Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Campaign launched to spread awareness regarding dengue prevention and control
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
This transaction is the third acquisition by three different Japanese players in this segment
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Subscribe To Our Newsletter & Stay Updated